Literature DB >> 2523865

Soluble forms of CD21 and CD23 antigens in the serum in B cell chronic lymphocytic leukaemia.

J Lowe1, B Brown, D Hardie, P Richardson, N Ling.   

Abstract

By using pairs of monoclonal antibodies (MAbs) to different epitopes on CD21 and CD23 antigens, it has been shown that both antigens are readily detectable in cell-free supernates of cultures of B cells expressing these antigens on the cell surface. The antigens remained in the soluble fraction after high speed centrifugation. Sera from normal individuals contained significant amounts of CD21 antigen, whereas little CD23 antigen was detectable. By contrast CD23 but not CD21 antigen was present in urine. Sera from patients with B cell chronic lymphocytic leukaemia (B-CLL) contained increased amounts of both antigens. The levels were related to the surface expression of antigen on the leukaemic cells and the number of cells in the blood. The possible functional role of soluble forms of B cell antigens and the diagnostic potential of their detection in body fluids are discussed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2523865     DOI: 10.1016/0165-2478(89)90093-x

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  12 in total

1.  Serum levels of soluble CD21 in patients with systemic sclerosis.

Authors:  Manabu Tomita; Takafumi Kadono; Norihito Yazawa; Tomohiko Kawashima; Zenshiro Tamaki; Ryuichi Ashida; Hanako Ohmatsu; Yoshihide Asano; Makoto Sugaya; Masahide Kubo; Hironobu Ihn; Kunihiko Tamaki; Shinichi Sato
Journal:  Rheumatol Int       Date:  2010-10-30       Impact factor: 2.631

Review 2.  Surface molecules involved in B lymphocyte function.

Authors:  P Möller; A Eichelmann; G Moldenhauer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

Review 3.  CD23: novel disease marker with a split personality.

Authors:  J Gordon
Journal:  Clin Exp Immunol       Date:  1991-12       Impact factor: 4.330

4.  Origin and properties of soluble CD21 (CR2) in human blood.

Authors:  N R Ling; D L Hardie; G D Johnson; I C MacLennan
Journal:  Clin Exp Immunol       Date:  1998-09       Impact factor: 4.330

5.  Urinary excretion of CD23 antigen in normal individuals and patients with chronic lymphocytic leukaemia (CLL)

Authors:  N R Ling; F K Stevenson; B Brown
Journal:  Clin Exp Immunol       Date:  1991-12       Impact factor: 4.330

6.  Enhanced CD21 expression and shedding in chronic lymphatic leukemia: a possible pathomechanism in disease progression.

Authors:  Hui Zhi Low; Dorothee Hilbrans; Ingo G H Schmidt-Wolf; Harald Illges
Journal:  Int J Hematol       Date:  2012-08-17       Impact factor: 2.490

7.  Cellular origins of serum complement receptor type 2 in normal individuals and in hypogammaglobulinaemia.

Authors:  N Ling; T Hansel; P Richardson; B Brown
Journal:  Clin Exp Immunol       Date:  1991-04       Impact factor: 4.330

8.  Determination of soluble CD21 as a parameter of B cell activation.

Authors:  H P Huemer; C Larcher; W M Prodinger; A L Petzer; M Mitterer; N Falser
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

9.  Antiphospholipid syndrome patients display reduced titers of soluble CD21 in their sera irrespective of circulating anti-beta2-glycoprotein-I autoantibodies.

Authors:  Anjana Singh; Miri Blank; Yehuda Shoenfeld; Harald Illges
Journal:  Rheumatol Int       Date:  2008-01-03       Impact factor: 2.631

10.  Systemic reduction of soluble complement receptor II/CD21 during pregnancy to levels reminiscent of autoimmune disease.

Authors:  Madhan Masilamani; Narendiran Rajasekaran; Anjana Singh; Hui-Zhi Low; Kerstin Albus; Swantje Anders; Frank Behne; Peter Eiermann; Katharina König; Clarissa Mindnich; Teodora Ribarska; Harald Illges
Journal:  Rheumatol Int       Date:  2008-05-24       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.